Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors.
Scheuplein F, Renner F, Campbell JE, Campbell R, De Savi C, Eckmann J, Fischer H, Ge J, Green L, Jakob P, Kim JL, Kinkema C, McGinn K, Medina R, Müller A, Perez N, Perola E, Timsit Y, Traore T, Hopfer U, Tyanova S, Tzouros M, Wang R, Woessner R, Dorsch M, Bischoff JR. Scheuplein F, et al. Among authors: woessner r. Front Immunol. 2024 Oct 21;15:1411395. doi: 10.3389/fimmu.2024.1411395. eCollection 2024. Front Immunol. 2024. PMID: 39502695 Free PMC article.
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma.
Schalm SS, O'Hearn E, Wilson K, LaBranche TP, Silva G, Zhang Z, DiPietro L, Bifulco N, Woessner R, Stransky N, Sappal D, Campbell R, Lobbardi R, Palmer M, Kim J, Ye C, Dorsch M, Lengauer C, Guzi T, Kadambi V, Garner A, Hoeflich KP. Schalm SS, et al. Among authors: woessner r. Gastro Hep Adv. 2022 Nov 8;2(3):307-321. doi: 10.1016/j.gastha.2022.11.004. eCollection 2023. Gastro Hep Adv. 2022. PMID: 39132655 Free PMC article.
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.
Lim SM, Schalm SS, Lee EJ, Park S, Conti C, Millet YA, Woessner R, Zhang Z, Tavera-Mendoza LE, Stevison F, Albayya F, Dineen TA, Hsieh J, Oh SY, Zalutskaya A, Rotow J, Goto K, Lee DH, Yun MR, Cho BC. Lim SM, et al. Among authors: woessner r. Ther Adv Med Oncol. 2024 Oct 21;16:17588359241280689. doi: 10.1177/17588359241280689. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39444426 Free PMC article.
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.
Ji Y, Calonder C, Kirsilä T, Burciu A, Tisu M, Joubert Y, Laurent N, Hua E, Patekar M, Drollmann A, Woessner R. Ji Y, et al. Among authors: woessner r. Pharmaceutics. 2023 Sep 1;15(9):2266. doi: 10.3390/pharmaceutics15092266. Pharmaceutics. 2023. PMID: 37765235 Free PMC article.
Severe olanzapine-induced liver function test elevation.
Crouse E, Woessner R. Crouse E, et al. Among authors: woessner r. Ment Health Clin. 2023 Jan 5;12(6):360. doi: 10.9740/mhc.2022.12.360. eCollection 2022 Dec. Ment Health Clin. 2023. PMID: 36644584 Free PMC article. No abstract available.
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.
Eno MS, Brubaker JD, Campbell JE, De Savi C, Guzi TJ, Williams BD, Wilson D, Wilson K, Brooijmans N, Kim J, Özen A, Perola E, Hsieh J, Brown V, Fetalvero K, Garner A, Zhang Z, Stevison F, Woessner R, Singh J, Timsit Y, Kinkema C, Medendorp C, Lee C, Albayya F, Zalutskaya A, Schalm S, Dineen TA. Eno MS, et al. Among authors: woessner r. J Med Chem. 2022 Jul 28;65(14):9662-9677. doi: 10.1021/acs.jmedchem.2c00704. Epub 2022 Jul 15. J Med Chem. 2022. PMID: 35838760 Free PMC article.
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
Schiller H, Huth F, Schuhler C, Drollmann A, Kaul M, Woessner R, Shah B, Weis W, End P. Schiller H, et al. Among authors: woessner r. Eur J Pharm Sci. 2022 May 1;172:106155. doi: 10.1016/j.ejps.2022.106155. Epub 2022 Mar 3. Eur J Pharm Sci. 2022. PMID: 35247543 Free article.
110 results